Real-world data show a rise in biomarker testing for primary advanced/recurrent endometrial cancer, especially mismatch repair/microsatellite instability, but disparities in access persist across care...
A phase 3 trial subgroup analysis found that adding pembrolizumab to adjuvant chemotherapy may improve disease-free survival in patients with mismatch repair-deficient endometrial cancer, a population at...
A randomized trial found that radiation therapy alone provides better progression-free survival and fewer acute toxicities than chemoradiation for women with localized recurrent endometrial cancer.
